Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drug Regulation01:25

Drug Regulation

3.2K
Drug regulation encompasses the management of drug usage by evaluating its safety and efficacy through assessments conducted by regulatory authorities. Regrettably, the history of drug regulation is marred by several catastrophic events. One such incident is the Elixir Sulfanilamide tragedy, in which the toxic compound diethyl glycol was included in a sweet-tasting medication, leading to numerous fatalities. This event prompted the enactment of the Food, Drug, and Cosmetic Act in 1938. Under...
3.2K
Clinical Trials: Overview01:11

Clinical Trials: Overview

5.2K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
5.2K
FDA Approved Drugs: Changes to Approved Drugs01:26

FDA Approved Drugs: Changes to Approved Drugs

296
Post-approval, manufacturers may modify an approved new or generic drug product. Such modifications can encompass alterations in the Active Pharmaceutical Ingredient (API), manufacturing process, formulation, batch size, manufacturing site, and container closure system (FDA Guidance for Industry, April 2004). Often, a drug product may undergo multiple changes.These modifications require careful evaluation to determine their potential impact on the drug product's identity, strength, quality,...
296
Preclinical Development: Overview01:28

Preclinical Development: Overview

6.2K
Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...
6.2K
Drug Administration and Therapy Phases: Overview01:26

Drug Administration and Therapy Phases: Overview

1.6K
Drugs, the chemical agents used in diagnosing, treating, or preventing diseases, undergo a four-phase process of development: pharmaceutic, pharmacokinetics, pharmacodynamics, and therapeutic.
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...
1.6K
Clinical Trials01:16

Clinical Trials

11.0K
Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
11.0K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Pursuing societal impact in research projects on NAM development: An analysis of routes to impact.

NAM journal·2026
Same author

HTA submission strategies and their associations with rollout times and type of HTA recommendation in Australia and Canada.

International journal of technology assessment in health care·2026
Same author

Safety population size and duration of exposure prior to approval of new medicines: A database analysis of medicines centralised approved in the European Union between 2011 and 2023.

PloS one·2026
Same author

Gaining regulatory acceptance for novel technologies in nonclinical drug development: A scoping review of its conceptualization in scientific literature.

Drug discovery today·2026
Same author

Assessment of compliance with good review practices by medicine assessors within the Zambia medicines regulatory authority.

Frontiers in medicine·2025
Same author

Harmonizing health: a global analysis of pharmaceutical regulatory activities by international regulatory organizations.

Frontiers in medicine·2025

Related Experiment Video

Updated: Mar 4, 2026

A Web Tool for Generating High Quality Machine-readable Biological Pathways
08:01

A Web Tool for Generating High Quality Machine-readable Biological Pathways

Published on: February 8, 2017

18.6K

FDA Facilitated Regulatory Pathways: Visualizing Their Characteristics, Development, and Authorization Timelines.

Lawrence Liberti1,2, Magda Bujar1, Alasdair Breckenridge3

  • 1Centre for Innovation in Regulatory ScienceLondon, UK.

Frontiers in Pharmacology
|April 20, 2017
PubMed
Summary
This summary is machine-generated.

Combining FDA facilitated regulatory pathways (FRPs) significantly shortens drug development and review times. Utilizing multiple FRPs, such as Breakthrough Therapy (BTD) and Accelerated Approval (AA) with Priority Review (PR), offers greater time savings than PR alone.

Keywords:
Accelerated ApprovalBreakthrough TherapyFDAFast TrackPriority Reviewfacilitated regulatory pathwayreview times

More Related Videos

Author Spotlight: Addressing Regulatory Gaps in Molecular Studies by Quantifying Viral Vectors in Complex Matrices
07:43

Author Spotlight: Addressing Regulatory Gaps in Molecular Studies by Quantifying Viral Vectors in Complex Matrices

Published on: July 14, 2023

2.9K
Author Spotlight: Advancements in CAR-T Cell Manufacturing and Gene Therapy Production
06:18

Author Spotlight: Advancements in CAR-T Cell Manufacturing and Gene Therapy Production

Published on: August 18, 2023

3.8K

Related Experiment Videos

Last Updated: Mar 4, 2026

A Web Tool for Generating High Quality Machine-readable Biological Pathways
08:01

A Web Tool for Generating High Quality Machine-readable Biological Pathways

Published on: February 8, 2017

18.6K
Author Spotlight: Addressing Regulatory Gaps in Molecular Studies by Quantifying Viral Vectors in Complex Matrices
07:43

Author Spotlight: Addressing Regulatory Gaps in Molecular Studies by Quantifying Viral Vectors in Complex Matrices

Published on: July 14, 2023

2.9K
Author Spotlight: Advancements in CAR-T Cell Manufacturing and Gene Therapy Production
06:18

Author Spotlight: Advancements in CAR-T Cell Manufacturing and Gene Therapy Production

Published on: August 18, 2023

3.8K

Area of Science:

  • Drug regulatory affairs
  • Pharmaceutical development
  • Clinical trial acceleration

Background:

  • The US Food and Drug Administration (FDA) offers four facilitated regulatory pathways (FRPs): Fast Track (FT), Breakthrough Therapy (BTD), Priority Review (PR), and Accelerated Approval (AA).
  • Only Priority Review (PR) mandates an expedited review timeline of 6 months.
  • The impact of combining multiple FRPs on drug development and approval durations remains incompletely understood.

Purpose of the Study:

  • To investigate the extent to which combining two or more FDA facilitated regulatory pathways (FRPs) influences drug development and approval timelines.
  • To compare the effectiveness of single FRPs versus combinations of FRPs in accelerating regulatory processes.

Main Methods:

  • Analysis of 125 new active substances approved between January 2013 and December 2015.
  • Assessment of 74 substances that utilized one or more FRPs.
  • Development of a "metro map" visualization to illustrate FRP elements and their impact on review times.

Main Results:

  • Development times varied significantly, from 1,458 days (BTD + PR + AA) to 3,515 days (PR alone).
  • Priority Review (PR) alone had a median approval time of 242 days.
  • The combination of Fast Track (FT) + Priority Review (PR) was most common (n=21), with a median approval time of 292 days.
  • The fastest approval times were observed for PR + FT + BTD + AA (145 days) and PR + BTD + AA (166 days).

Conclusions:

  • Combining multiple FDA facilitated regulatory pathways (FRPs) demonstrably shortens drug development and review timelines.
  • The synergistic effect of multiple FRPs provides greater time efficiencies than Priority Review (PR) alone.
  • Strategic utilization of combined FRPs can accelerate the availability of new therapies to patients.